Topic: APP/PS1 transgenic mice

In the past decade, an increasing number of studies have been focusing on identifying Alzheimer’s disease (AD)-related epigenetic modifications, both in humans and mouse models. Recently, it has been shown that late-stage AD human samples show alterations in histone modifications, chromatin compartmentalisation, and chromatin structural protein localisation (Xiong et al., Cell, 2023). These changes collectively result in epigenome erosion. However, the mechanisms and the role of chromatin structural proteins underpinning this event remain unclear. Likewise, it remains uncertain whether cogniti

Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) and tau neuropathology, neuroinflammation, lipid dysregulation, and progressive loss of cognitive functioning. We have evidence that early dietary interventions with ω6/ω3 polyunsaturated fatty acids (PUFAs) can protect against cognitive decline and lastingly alter microglia and brain lipid profile in the context of early-life stress​. PUFAs can directly modulate microglia. In the context of AD, it is unknown if lipid and PUFA derivatives (oxylipins) are dysregulated in the brain, how these rel